Date: 2015-05-04
Type of information: Collaboration agreement
Compound: NanomAbs
Company: Immune Pharmaceuticals (Israel) STC Biologics (USA - MA)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration development
Action mechanism: monoclonal antibody/antibody drug conjugate. The NanomAb technology has been licensed by Immune from Yissum, the Technology Transfer company of the Hebrew University of Jerusalem and was originally developed by Professor Benita, former Director of the Institute for Drug Research at the Hebrew University of Jerusalem.
Disease:
Details: * On May 4, 2015, Immune Pharmaceuticals, a clinical stage bio-pharmaceutical company with a first-in-class monoclonal antibody, bertilimumab, for the treatment of auto-immune diseases, and STC Biologics, a biotechnology development company led by alumni of Genentech, Shire, Novartis and Merrimack Pharmaceuticals, announced that they are entering into a strategic partnership to accelerate the development of NanomAbs, a new generation of Antibody Nanoparticle Conjugates allowing the targeted delivery of chemo-therapeutics. The Immune Pharmaceuticals-STC Biologics strategic partnership will leverage research capabilities of STC in Cambridge, MA and Immune in Jerusalem, Israel. Development will initially focus on HER2-targeted paclitaxel nanoparticles using an anti-HER2 monoclonal antibody developed by STC, and H-Ferritin targeted paclitaxel nanoparticles using an anti-H Ferritin monoclonal antibody developed by Immune. Licensing and joint-development agreements between STC and Immune are expected to be finalized during the second quarter 2015.
Financial terms:
Latest news:
